Literature DB >> 33527056

Leukocytapheresis in Chronic Myeloid Leukemia With Leukostasis.

Babita Raghuwanshi1, Sunil Chouhan2, Anuj Jain3.   

Abstract

Leukostasis in acute and chronic leukemias leads to increased cell burden and increased blood viscosity. Therapeutic leukocytapheresis is an automated procedure aimed at white blood cell depletion, and it thereby reduces the complications associated with increased blood viscosity, such as thrombotic events and mortality. In this report, we present the case of a 25-year-old patient with leukostasis and splenic laceration who was treated with therapeutic leukocytapheresis with symptomatic relief in leukostasis.
Copyright © 2020, Raghuwanshi et al.

Entities:  

Keywords:  chronic leukemias; leukostasis; therapeutic leukocytapheresis

Year:  2020        PMID： 33527056      PMCID： PMC7845160          DOI： 10.7759/cureus.12375

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  7 in total

1.  Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue.

Authors:  Joseph Schwartz; Jeffrey L Winters; Anand Padmanabhan; Rasheed A Balogun; Meghan Delaney; Michael L Linenberger; Zbigniew M Szczepiorkowski; Mark E Williams; Yanyun Wu; Beth H Shaz
Journal:  J Clin Apher       Date:  2013-07       Impact factor: 2.821

2.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.

Authors:  Anand Padmanabhan; Laura Connelly-Smith; Nicole Aqui; Rasheed A Balogun; Reinhard Klingel; Erin Meyer; Huy P Pham; Jennifer Schneiderman; Volker Witt; Yanyun Wu; Nicole D Zantek; Nancy M Dunbar; Guest Editor Joseph Schwartz
Journal:  J Clin Apher       Date:  2019-06       Impact factor: 2.821

Review 3.  Hyperleukocytosis, leukostasis and leukapheresis: practice management.

Authors:  Chezi Ganzel; Joanne Becker; Paul D Mintz; Hillard M Lazarus; Jacob M Rowe
Journal:  Blood Rev       Date:  2012-02-23       Impact factor: 8.250

4.  Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome.

Authors:  J R Novotny; H Müller-Beissenhirtz; S Herget-Rosenthal; A Kribben; U Dührsen
Journal:  Eur J Haematol       Date:  2005-06       Impact factor: 2.997

5.  Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia.

Authors:  Kristina Hölig; Rainer Moog
Journal:  Transfus Med Hemother       Date:  2012-07-26       Impact factor: 3.747

Review 6.  The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Authors:  Priyanka A Pophali; Mrinal M Patnaik
Journal:  Cancer J       Date:  2016 Jan-Feb       Impact factor: 3.360

7.  A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia.

Authors:  Yanxia Jin; Shishang Guo; Qin Cui; Sichao Chen; Xiaoping Liu; Yongchang Wei; Yunbao Pan; Liang Tang; Tingting Huang; Hui Shen; Guanghui Xu; Xuelan Zuo; Shangqin Liu; Hui Xiao; Fei Chen; Fayun Gong; Fuling Zhou
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.